Skip to main content
All lobbying filings

CGCN GROUP, LLC

Lobbying for EMERGENT BIOSOLUTIONS INC. · Biopharmaceutical Company

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $70,000.00 income · posted Jul 19, 2026

Official filing document

 Bills named in this filing 4
  • HR 8800
    National Defense Authorization Act for Fiscal Year 2027
  • S 4784
    National Defense Authorization Act for Fiscal Year 2027
  • HR 5252
    HOPE Act
  • HR 8870
    BUILD America 250 Act
 Lobbying activity 4
Disaster Planning/Emergencies

Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).

Health Issues

Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).

Homeland Security

Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).

Budget/Appropriations

Reauthorization of Protecting Americans from All-Hazards Preparedness Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY27; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY27; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY27; Tribal Opioid Response Grant funding for FY27; H.R. 8800/S. 4784 - NDAA for Fiscal Year 2027 - provisions related to biological and chemical defense and access to naloxone; H.R. 5252, Having Overdoes Protection Equipment Act; Reauthorization of the surface transportation program last included in the Infrastructure Investments and Jobs Act (H.R. 8870, S. TBD).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem